Asabys Partners

We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences. We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel. We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development. We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers. An overall positive impact that will produce intrinsic value for both investors and society.

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

We build breakthrough biotechnology companies. Exceptional entrepreneurs and scientists translate innovation into novel medicines. We play the long game with urgency. Patience, discipline, and vision to bring new transformational medicines to life. We are relentless truth-seekers. Our seed-led investment model uncovers the most promising opportunities. We understand the power of community. We prioritize a collaborative, science-first, patient-centric culture.

Biospring Partners was founded in 2020 to invest in companies with the potential to fundamentally shift how technology is utilized across the life sciences sector. Michelle Dipp and Jennifer Lum came together to combine their experience in healthcare, technology, investing and operations to offer a differentiated approach to growth equity. Expanding the potential of life sciences technology We focus on identifying long-term themes within life sciences technology. We build trusted partnerships with management teams to support the growth of their businesses. Sectors we invest in Biospring invests in growth-stage B2B companies that are driving innovation across the life sciences industry and beyond. Our Approach We are a trusted partner that thrives in building long term strategic partnerships. We work closely alongside our companies to broaden their ambition and strengthen their path to growth. Our Investment Criteria$10M+ in annual revenue 30%+ revenue growth Diverse customer base

We are an investment firm with more than 25 years of experience backing transformational healthcare and biotech companies. We see the world through an entrepreneur’s eyes. We thrive on collaborating with groundbreaking innovators and repeat entrepreneurs. Our roots are deep in healthcare and science. We have built and nurtured our network over more than two decades – including some of the world’s most prestigious companies, syndicate partners, universities and research institutions. We have built and nurtured our network over more than two decades – including some of the world’s most prestigious companies, syndicate partners, universities and research institutions. Groundbreaking expertiseHealthcare: Our healthcare portfolio companies target innovative care delivery models, such as digital health, consumer-centric businesses, patient and provider solutions, and data science and analytics. Life sciences and biotechnology: Our life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics and genomics.

We are a Venture Capital firm founded by leading experts in the fields of science, technology, medicine, business, and finance. We are initially focused on global medical technology. With over 40 patents and multiple successful ventures amongst the founders, we have a proven track record of astute medical and technology investment management. We don't just invest, we build, nurture and curate our community of ventures to be the best they can. We believe that with an increasing global population, an aging and ailing population in developed economies and with increases in non-communicable diseases, there exists a unique opportunity for investors to capitalise on high growth medical technology and life sciences that will not only drive high returns for investors but make the world a better place through improved quality of life.